Resources

By Christian Cobaugh, CEO and Founder Monoclonal antibodies (mAbs) have emerged as one of the most successful drug products and biochemical reagents of the 21st century, owing to their broad range of activities, target specificity, and ease of manufacturing. There are now several successful platforms available to discover and engineer novel antibodies with desirable drug-like…

We cannot believe it has been 2 years. Happy Birthday Vernal Biosciences! See how Vernal has grown since 2021 and expanded its capabilities for mRNA, LNP, and GMP!

Sorry we missed you at the World Vaccine Congress in DC this April (2023). As previously mentioned, we showcased our poster providing information on the efficacy of LNP-mRNA using Sars-Cov-2 spike protein to demonstrate. We encourage you to download our poster here and see the data. Feel free to contact us at [email protected] for further…

By Julia Sakamoto, Marketing Specialist The development of mRNA vaccines has been ongoing since the late 80s, but it wasn’t until the COVID-19 pandemic that this technology became widely recognized.  Instead of using an antigen to trigger the body’s immune system to create a new antibody, mRNA can give direct instructions on how to fight…

Vernal’s mission has always been to democratize access to mRNA. One of the ways we are achieving this is expanding our capabilities in mRNA process and development so that we can provide GMP for clinical use cases. Take a look at our newsletter for a snapshot on how we are moving towards this goal!

Didn’t have a chance to attend the 2022 mRNA Health Conference and talk about mRNA manufacturing needs for your projects? Download a copy of our poster regarding the “Design, formulation, and manufacturing of LNP-mRNA for clinically relevant applications” authored by our very own LNP SMEs, Elias Henderson, Noah T. Prugar, Lynda M. Menard, and Joseph…